International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(17), P. 13429 - 13429
Published: Aug. 30, 2023
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative brain disorder that represents the most common type of dementia. It poses a significant diagnostic challenge requires timely recognition and treatment. Currently, there no effective therapy for AD; however, certain medications may slow down its progression. The discovery AD biomarkers, namely, magnetic resonance imaging, positron emission tomography cerebrospinal fluid molecules (amyloid-β tau) has advanced our understanding this been crucial identifying early neuropathologic changes prior to clinical cognitive decline. close interrelationship between eye suggests tears could be interesting source biomarkers studies in area are limited. identification will enable development cost-effective, non-invasive methods screening, diagnosis monitoring. In order use as standard method AD, future need conducted on larger scale.
Language: Английский
Citations
23Tear biomarkers
Advances in clinical chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 69 - 115
Published: Jan. 1, 2024
Language: Английский
Citations
9Topical review: Ocular surface abnormalities in neurodegenerative disorders
Optometry and Vision Science, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 9, 2025
SIGNIFICANCE In an aging population, the number of people living with neurodegenerative disease is projected to increase. It vital develop reliable, noninvasive biomarkers detect onset and monitor progression, there a growing body research into ocular surface as potential source such biomarkers. BACKGROUND This article reviews in vivo corneal confocal microscopy tear fluid analysis tools for biomarker development. Corneal microscopy, traditionally used studying health, offers high-resolution imaging nerves has shown promise examining systemic diseases Alzheimer Parkinson's disease. Complementarily, analysis, known its ease collection, reflects changes conditions. CONCLUSION Together, these techniques provide insights progression hold advancing diagnostic treatment strategies.
Language: Английский
Citations
1Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Frontiers in Aging Neuroscience, Journal Year: 2024, Volume and Issue: 16
Published: Aug. 9, 2024
The most prevalent cause of dementia is Alzheimer's disease. Cognitive decline and accelerating memory loss characterize it. disease advances sequentially, starting with preclinical stages, followed by mild cognitive and/or behavioral impairment, ultimately leading to dementia. In recent years, healthcare providers have been advised make an earlier diagnosis Alzheimer's, prior individuals developing Regrettably, the identification early-stage in clinical settings can be arduous due tendency patients disregard symptoms as typical signs aging. Therefore, accurate prompt essential order facilitate development disease-modifying secondary preventive therapies onset symptoms. There has a notable shift goal process, transitioning from merely confirming presence symptomatic AD recognizing illness its early, asymptomatic phases. Understanding evolution putting effective diagnostic therapeutic management into practice requires understanding this concept. outcomes study will enhance in-depth knowledge current status disease's treatment, justifying necessity for quest potential novel biomarkers that contribute determining stage disease, particularly earliest stages. Interestingly, latest trial on pharmacological agents, nonpharmacological treatments such behavior modification, exercise, training well alternative approach phytochemicals neuroprotective agents covered detailed.
Language: Английский
Citations
8Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers
Molecules, Journal Year: 2024, Volume and Issue: 29(3), P. 722 - 722
Published: Feb. 4, 2024
Alzheimer’s Disease (AD) and Parkinson’s (PD) represent two among the most frequent neurodegenerative diseases worldwide. A common hallmark of these pathologies is misfolding consequent aggregation amyloid proteins into soluble oligomers insoluble β-sheet-rich fibrils, which ultimately lead to neurotoxicity cell death. After a hundred years research on subject, this only reliable histopathological feature in our hands. Since AD PD are diagnosed once neuronal death first symptoms have appeared, early detection currently impossible. At present, there no effective drug available, patients left with symptomatic inconclusive therapies. Several reasons could be associated lack therapeutic treatments. One important factors selective probes capable detecting, as possible, toxic species involved onset pathologies. In regard, chemical able detect distinguish different aggregates urgently needed. article, we will review put perspective results from ex vivo studies performed compounds specifically interacting such species. Following general overview three leading deposits (amyloid β1–42 peptide, Tau, α-synuclein), list advantages disadvantages approaches employed date discussed, particular attention paid translation fluorescence imaging clinical applications. Furthermore, also discuss how progress achieved detecting amyloids one disease leveraged for another amyloidosis. As evidenced by critical analysis state art, substantial work still needs conducted. Indeed, diagnosis priority, believe that useful tool better investigating field.
Language: Английский
Citations
6Multi-tissue proteomic signatures of Alzheimer's disease: a systematic investigation in brain, CSF, blood and an exploratory study in tears
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Abstract Proteomic studies have the potential to identify etiological biomarker and interventional targets for Alzheimer’s disease (AD). However, limited systematically investigated compared proteomic profiling related AD across multiple tissues. First, we reviewed 112 of (comprising 107 case-control 16,997 individuals 5 prospective cohort 60,782 individuals) synthesized a map 902 brain bulk, 315 cerebrospinal fluid (CSF), 9 blood markers that were consistently altered in at least studies. In particular, total 55 common proteins same direction bulk CSF, whereas 33 opposite direction. Next, applied proteome-wide Mendelian randomization identified 28 brain, 32 59 plasma genetically predicted associated with (all FDR < 0.05). The comparison tissues uncovered panel 20 AD-related two human Overall, pool 1,219 multi-tissue high confidence two-phase investigation. exploratory analysis utilizing matched study among 79 community-dwelling older adults, detected 845 protein tears, which 312 severity-dependent manner normal cognition controls, mild cognitive impairment (MCI) dementia stages. Among these, levels STXBP1, UBE2V1, PALM, PYGB, ST13, GPD1 significantly different or MCI controls P our provides comprehensive roadmap biomarkers help enhance exploration underlying mechanisms, facilitate development minimally invasive screening methods, novel interventions.
Language: Английский
Citations
0Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids
S S Korsakov Journal of Neurology and Psychiatry, Journal Year: 2025, Volume and Issue: 125(1), P. 8 - 8
Published: Feb. 11, 2025
One of the urgent problems modern health care is Alzheimer’s disease (AD) and its early diagnosis. This due to rapid global spread AD, lack pathogenetic therapy, ability stabilize progression cognitive impairment in stages disease. Currently, only an autopsy can confirm diagnosis AD with 100% reliability, classical laboratory instrumental methods verification are difficult implement routine clinical practice several limitations. That why study new available biomarkers identified human bodily fluids promising for AD. The review addresses problem using markers fluids, which be obtained a non-invasive way. Potential saliva, tear fluid, urine, nasal secretion reviewed, their prognostic values as indicators stage evaluated.
Language: Английский
Citations
0Global practices of tear fluid collection, storage, and molecular analysis – A questionnaire by the Tear Research Network
Contact Lens and Anterior Eye, Journal Year: 2025, Volume and Issue: unknown, P. 102388 - 102388
Published: March 1, 2025
Language: Английский
Citations
0Fluid-based biomarkers for neurodegenerative diseases
Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102739 - 102739
Published: March 1, 2025
Language: Английский
Citations
0The Major Hypotheses of Alzheimer’s Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment
Cells, Journal Year: 2023, Volume and Issue: 12(23), P. 2669 - 2669
Published: Nov. 21, 2023
Alzheimer’s disease (AD) is a well-known chronic neurodegenerative disorder that leads to the progressive death of brain cells, resulting in memory loss and other critical body functions. In March 2019, one major pharmaceutical companies its partners announced currently, there no drug cure AD, all clinical trials new ones have been cancelled, leaving many people without hope. However, despite clear message startling reality, research continued. Finally, last two years, Food Drug Administration (FDA) approved first-ever medications treat Alzheimer’s, aducanumab lecanemab. Despite researchers’ support this decision, are serious concerns about their effectiveness safety. The validation by Centers for Medicare Medicaid Services still pending, lecanemab was authorized considering data from phase III trials. Furthermore, numerous reports suggest patients died when undergoing extended treatment. While evidence may provide some relief those suffering impact remains topic ongoing debate within medical community. fact even though considerable efforts regarding pharmacological treatment, definitive AD has found yet. Nevertheless, it strongly believed modern nanotechnology holds promising solutions effective strategies development diagnostic tools treatments AD. This review summarizes hallmarks etiological mechanisms, challenges. It explores existing therapeutic methods potential nanotechnology-based approaches recognizing monitoring at risk irreversible neuronal degeneration. Overall, provides broad overview interested evolving areas neuroscience, related nanotechnology. With further development, offer hope millions affected devastating disease.
Language: Английский
Citations
10